Science Corporation, a brain-computer interface (BCI) developer founded by Neuralink co-founder Max Hodak, has acquired the intellectual property (IP) and related assets for the Pixium Vision Prima implant. This acquisition includes the retinal implant technology developed by Pixium Vision. The Prima System, which is a photovoltaic substitute of photoreceptors, has already received FDA breakthrough device designation. It is designed for patients with atrophic dry age-related macular degeneration (AMD) and allows for simultaneous use of central prosthetic and peripheral natural vision.
Science Corporation saw an opportunity to further develop BCI technology for vision restoration through the acquisition of the Prima System. The company already has Science Eye, another product developed by Science Corporation, which is a visual prosthesis targeting retinitis pigmentosa (RP) and dry AMD. The addition of the Prima implant technology will expand their IP portfolio and provide continuity and a future for patients enrolled in Pixium clinical trials.
CEO Max Hodak expressed excitement about the acquisition, stating that Science Corporation is now developing innovative products using two different modalities. He believes that the Prima implant will help continue their mission of helping patients with vision impairments. Outgoing Pixium CEO Lloyd Diamond expressed confidence in the acquisition, believing that Prima now has a home with a team dedicated to helping patients. The terms of the deal were not disclosed, but both companies are committed to working together to advance BCI technology for the benefit of patients.
In summary, Science Corporation’s acquisition of the IP and related assets for the Pixium Vision Prima implant expands their portfolio and provides continuity for patients enrolled in clinical trials. With this new addition to their product lineup, Science Corporation continues its mission to help patients with vision impairments through innovative BCI technology development.
